↓ Skip to main content

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

Overview of attention for article published in OncoTargets and therapy, May 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

1 news outlet


41 Dimensions

Readers on

51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Published in
OncoTargets and therapy, May 2011
DOI 10.2147/ott.s18155
Pubmed ID

Ballas, Chachoua


Lung cancer remains a leading cause of death globally, with the most frequent type, nonsmall cell lung cancer (NSCLC), having a 5-year survival rate of less than 20%. While platinum-based doublet chemotherapy is currently first-line therapy for advanced disease, it is associated with only modest clinical benefits at the cost of significant toxicities. In an effort to overcome these limitations, recent research has focused on targeted therapies, with recently approved agents targeting the epidermal growth factor receptor and vascular endothelial growth factor (VEGF) signaling pathways. However, these agents (gefitinib, erlotinib, and bevacizumab) provide antitumor activity for only a small proportion of patients, and patients whose tumors respond inevitably develop resistance to treatment. As angiogenesis is a crucial step in tumor growth and metastasis, antiangiogenic treatments might be expected to have antitumor activity. Important targets for the development of novel antiangiogenic therapies include VEGF, fibroblast growth factor, platelet-derived growth factor, and their receptors. It is hypothesized that targeting multiple angiogenic pathways may not only improve antitumor activity but also reduce the risk of resistance. Several novel agents, such as BIBF 1120, sorafenib, sunitinib, and cediranib have shown promising preliminary activity and tolerability in Phase II studies, and results of ongoing Phase III randomized studies will be necessary to establish the potential place of these new therapies in the management of individual patients with NSCLC.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 2%
Unknown 50 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 24%
Student > Ph. D. Student 7 14%
Other 7 14%
Student > Master 4 8%
Student > Postgraduate 3 6%
Other 11 22%
Unknown 7 14%
Readers by discipline Count As %
Medicine and Dentistry 17 33%
Agricultural and Biological Sciences 12 24%
Biochemistry, Genetics and Molecular Biology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Business, Management and Accounting 1 2%
Other 4 8%
Unknown 10 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2014.
All research outputs
of 12,475,053 outputs
Outputs from OncoTargets and therapy
of 1,548 outputs
Outputs of similar age
of 190,692 outputs
Outputs of similar age from OncoTargets and therapy
of 21 outputs
Altmetric has tracked 12,475,053 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,548 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,692 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.